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Abstract
Background: In the UK, diabetes accounts for approximately 10% of the total UK National Health Service (NHS)
resource expenditure, a figure that has been predicted to increase to 17% by 2035/2036. Meta-analysis of association
studies indicate that yogurt consumption is potentially protective against type 2 diabetes (T2D). The purpose of this
study was to explore the potential economic benefit to the UK NHS of a population increase in yoghurt consumption
as a preventative measure against development of T2D.
Methods: A patient simulation model was constructed for adults in the UK over the age of 25 years old using incidence
rates for developing T2D with both current and increased yoghurt consumption. The reduction in risk in developing T2D
associated with higher yoghurt consumption was taken from a meta-analysis of studies of dairy consumption on T2D risk.
In each annual cycle of the model a patient could develop complications and comorbidities that are known to be more
common in patients with T2D. Incidence rates for these conditions for diabetics and non-diabetics were taken
from published studies. The model had a 25 year time horizon.
Results: The model predicts that increasing average yoghurt consumption by adults over 25 years of age in the UK by
100g daily could result in 388,000 fewer people developing T2D over 25 years. This could save the UK NHS £2.3bn in
direct T2D treatment costs and the costs of treating T2D associated complications. In addition, 267,000 QALYs would
be generated. If the NHS values a QALY valued at £20,000, this would mean that the NHS should be prepared to pay
£5.5bn for an intervention that generated the same number of QALYs.
Conclusions: Increasing yoghurt consumption in the adult population of the UK by 100g per day could generate
substantial cost savings to the NHS as well as significant patient benefit through reductions in the incidence of T2D.
Keywords: Yoghurt, Type 2 diabetes, T2D, Economic model
Background
The prevalence of type 2 diabetes (T2D) is rapidly rising
and now affects 9% of the global population [1] and is
projected to be the seventh leading cause of death by
2030 [2]. Between 2010 and 2030, the prevalence of
diabetes has been forecast to increase by 20% in de-
veloped countries and 69% in developing counties [3].
In 2015, the costs of diabetes and related complica-
tions accounted for 12% of global healthcare budgets,
or between USD673 billion and USD1,197 billion [4].
Lifestyle interventions can prevent or delay some
cases of T2D and thus reduce the huge economic
burden of diabetes [5]. There is an increasing focus
on pinpointing food groups that can be used to re-
duce chronic conditions, and evidence is emerging
that dairy products may play an important role in
metabolic disease and T2D prevention and manage-
ment [6]. Dairy products are an important source of
protein, fats, vitamins and minerals, but many also
contain a proportion of saturated fatty acids (SFAs)
[7] which are commonly thought to have a negative
effect on cardiometabolic health [8]. However, recent
investigations indicate that some types of SFA may
actually be beneficial to T2D management; for example,
myristic acid has been associated with improved glucose
homeostasis [9, 10], and plasma levels of very long-chain
SFAs were inversely correlated with T2D incidence in the
EPIC-InterAct case-cohort study [11]. This may explain
why daily consumption of yoghurt has also been linked, in
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a large meta-analysis, to a lower risk of developing
T2D, an association that was not seen for general dairy
consumption suggesting that the nutritional compos-
ition of yoghurt may have specific benefits in T2D
prevention [12].
In the UK, diabetes accounts for approximately 10% of
the total UK National Health Service (NHS) resource
expenditure, a figure that has been predicted to increase
to 17% by 2035/2036 with 80% of this cost as a result of
complications [13]. Previous econometric research has
highlighted the potential cost effectiveness of dietary
interventions to prevent or delay the onset of T2D. “The
Mediterranean Diet” and the “Intensive Lifestyle Change
to Prevent Diabetes” have been cited as highly cost-
effective interventions gaining £410 and £750 per QALY
respectively [14]. The American Diabetes Association
(ADA) recommend several interventions for preventing
and treating T2D; a systematic review from 2010 indi-
cated that preventative interventions were the most
cost-effective, with the strongest evidence available for
“primary prevention through lifestyle modification” [15].
The purpose of this study was to explore the potential
economic benefit to the UK of an increase in yoghurt
consumption as a preventative measure against develop-
ment of T2D.
Methods
The primary research question was: How would an
increase in the average consumption of conventional
yoghurt impact upon UK health care expenditure in the
management and treatment of T2D? A supplementary
research question was: How would an increase in the
average consumption of conventional yoghurt impact
upon the quality and length of life for a UK population
based on cases of T2D avoided or delayed?
The model
The patient pathway is shown in Fig. 1 and was used to
build a patient simulation model in Microsoft Excel. To
summarise the pathway, a virtual subject enters the
Fig. 1 Patient pathway
Lenoir-Wijnkoop et al. BMC Nutrition  (2016) 2:77 Page 2 of 9
model with randomly assigned characteristics (age, gen-
der, pre-existing conditions). If he/she does not already
have T2D, the risk of developing the disease in each sub-
sequent year is reduced by higher yoghurt consumption.
In the model, each year a subject can develop one or
several complications, or die; for a subject who already
has T2D, the probability of developing a complication is
increased.
The modelled population was all people in the UK
aged over 25 years. Age and gender distributions were
taken from the Office for National Statistics (ONS)
population pyramid projections [16].
Effectiveness
Effectiveness was derived from Chen et al. [12], a large
study, combining 14 prospective cohorts and a total of
459,790 individuals, with 35,863 developing T2D within
4 million patient-years of follow-up. Based upon a cor-
relation between yoghurt consumption and developing
T2D, Chen estimated that for each additional serving of
244g of yoghurt, the relative risk (RR) of developing
T2D is 0.82. To undertake our modelling, we assumed
that the relationship was causative and that risk re-
duction occurs linearly with changes in yoghurt con-
sumption and adjusted for current average yoghurt
consumption in the UK of 20.4g per person per day [17].
In the base case model it was assumed that average daily
consumption would rise by 100g to reach 125g (a standard
size single serving ‘pot’ in the UK). This equated to a
change in the RR of developing T2D from 0.99 at
current consumption, to 0.91 if average consumption
increased to 125g daily. The RRs were estimated using
a linear interpolation between the RR associated with
no daily yoghurt consumption (0g, RR = 1), and the RR
associated with a daily serving (244g, RR = 0.82).
Costs
Throughout the model we have taken a conservative
approach. Costs incorporated into the model are con-
sidered in three categories: direct diabetes management
costs; hospital; and non-inpatient costs for treating
diabetes-related complications.
Diabetes management costs were taken from Hex
et al. [13], who reported a mean direct treatment cost
(including diabetic medications, primary care visits,
retinopathy screening, influenza vaccination and medical
examinations) of £513.54 per person with diabetes to the
UK NHS.
For treatment of complications, costs and resource use
were modelled using a recently published logit model
that looked at the UKPDS data on healthcare costs [18].
Costs included those for all admissions and inpatient
procedures as well as outpatient consultations with GPs,
nurses, health visitors, dieticians, chiropodists and eye
care specialists. Whether a condition required initial
hospitalisation and/or annual on-going treatment post
discharge was modelled through a random drawing of
the logit model. Parameters of the logit model are sum-
marised in Table 1.
The model conservatively considered that the prob-
ability of experiencing a particular event, or developing a
condition was independent of the presence of others.
However, the costs that could be incurred when an event
or condition arises could be dependent on the presence
of other conditions. For example, having a stroke would
not make it more likely a person had a myocardial in-
farction (MI) in the future but it would make it more
likely that an MI would lead to hospitalisation. Other
than for foot ulcers (which were considered as a one off
certainty of the cost of the event), only the first event of
each complication was considered in the model.
Specific additional costs were also identified to complete
the necessary inputs into the model:
 Heart failure and diabetic retinopathy – derived in
Sheffield Diabetes model (SDM) from older UKPDS
data [19];
 CKD – derived in SDM from NHS reference
costs [20];
 Foot ulcer – NHS diabetic foot care report [21].
Quality of Life
At the end of each cycle a person exists in an age and
disease specific health state. Each health state has an as-
sociated level of quality of life that is measured via utility
estimates from the literature. With the exception of am-
putation, all utility values were derived from Sullivan
[22] that estimated health states from 80,000 people in
the USA and applied UK utility weights to these health
states. For lower limb amputation, a utility value was
taken from Bagust [23].
The age and disease utility decrements used in the
model are given in Table 2. For cardiovascular condi-
tions, the maximum decrement of the three possible
conditions in the model was applied if more than one of
the conditions was experienced.
Once a condition is experienced, that utility decrement
exists for the remainder of the patient’s life (with the ex-
ception of foot ulcers). It is noted that the utility value is
an average value of people with both good and poor out-
comes after events.
Disease incidence and prevalence rates
Age specific prevalence rates of T2D and age and gender
specific prevalence rates of related comorbidities were
required to be able to estimate the likelihood of an indi-
vidual entering the model, already having T2D or an
associated comorbidity (with or without the presence of
Lenoir-Wijnkoop et al. BMC Nutrition  (2016) 2:77 Page 3 of 9
T2D). Similarly, age related incidence rates were re-
quired to move people through the model during each
annual cycle. The source of each of the incidence and
prevalence rates is shown in Table 3.
Relative risks of comorbid disease with T2D
The National Diabetes Audit 2011–2012 provided data
on the relative increase in the risk of comorbid disease
for people with T2D [24]. The audit recorded data from
2.5 million people in England and Wales. The increase
in risk for each condition is shown in Table 4.
Mortality
Mortality occurs in the model in two distinct ways; a
person may die from developing a particular condition
or event, such as cerebrovascular disease (stroke) or MI;
or a person may suffer an ‘all-other cause death’ based
upon age and gender derived all-cause mortality data.
Individual condition/event mortality rates were taken
from published sources shown in Table 5 and all other
cause mortality was sourced from the ONS [16].
Results
Results under the base case assumptions for 100,000
individuals cycled through the model were generated.
The average individual and total (extrapolated to all
people in the UK over 25) cost savings and QALY gains
from higher yoghurt consumption are shown in Tables 6
and 7.
The base case results – which are based on a conser-
vative approach to modelling potential benefits - show
that if the average daily consumption of yoghurt in the
UK for people over the age of 25 increased from 20.4g
to a 125g serving, discounted mean savings over five
Table 2 Utility decrements applied in the model
Condition Decrement
Age (per year) −0.00029
Diabetes −0.07
Ischemic heart disease −0.09
Heart failure −0.12
Myocardial infarction −0.06
CKD requiring RRT −0.11
Cerebrovascular disease (stroke) −0.10
Diabetic retinopathy −0.04
Blindness −0.06
Foot ulcer −0.07
Amputation −0.11
Table 1 Logit model values of costs associated with treating complications of T2D
Variable Logit model coefficient Hospital care (£) Non-patient care (£) Additional (£)
Constant –1.353 3318 531 -
Aged 65+ 0.041 38 4 -
Male −0.118 −218 −162 -
Event during current year Ischaemic heart disease (angina) 3.379 8636 331 -
Fatal Ischaemic heart disease 4.701 1037 - -
Heart failure 2.98 1147 447 -
Fatal heart failure - - - 3637
Myocardial infarction 4.506 3845 963 -
Fatal myocardial infarction 5.115 −1341 - -
CKD requiring RRT - - - 23275
Stroke 2.419 7133 559 -
Fatal stroke - 1042 - -
Diabetic retinopathy - - - 138
Blindness in one eye 0.825 1621 1258 -
Foot ulcer - - - 743.68
Amputation 4.059 7516 2166 -
Historic event Ischaemic heart disease (angina) 0.553 2042 121 -
Heart failure 0.824 2017 441 -
Myocardial infarction 0.68 1369 671 -
Stroke 0.37 2371 224 -
Blindness in one eye 0.266 −601 205 -
Amputation 1.254 1616 1079 -
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years to the NHS from reducing the rate of T2D and
T2D related complications would be £3.21 (95% CI:
£2.65, £3.77) per person. This saving would increase
each year up to and including the 25 years considered in
the model. By 25 years the saving per person from in-
creased yoghurt consumption would be £54.35 (£49.87,
£58.82).
Applying the average saving to the UK population over
the age of 25 would generate total discounted savings to
the NHS of approximately £140 million (£116m, £165m)
over five years that would increase to £2,377 million
(£2,181m, £2,573m) over 25 years if average consump-
tion increased to 125g.
From a quality of life perspective, if the average
consumption of yoghurt by people over 25 in the UK
increased to 125g per day, an average additional 0.0004
discounted QALYs (0.0003, 0.0005) per person over five
years would be generated; this would increase to an
additional 0.0063 discounted QALYs (0.0056 to 0.0070)
after 25 years. At a population level this would generate
approximately 276,352 (246,172, 306,532) total add-
itional discounted QALYs over 25 years. If these QALYs
were valued at £20,000/QALY as is usually applied by
NICE in the UK for approval of therapies, then the NHS
should be prepared to pay £5,500m over 25 years for an
intervention that would generate the same number of
QALYs.
Application of the 0.91 risk reduction of developing
T2D from average yoghurt consumption of 125g as
opposed to the 0.99 risk reduction from the current
average of 20.4g has a relatively modest impact on the
absolute annual risk of developing T2D in the model.
For people aged 60–69, the annual risk of developing
T2D in the model is reduced from 0.67% to 0.62%,
which was the largest absolute reduction for any age
group. However whilst the annual absolute risk reduc-
tion is modest, over time this reduction results in a sub-
stantial number of avoided incident cases of T2D.
In the base case, the model suggests that the absolute
reduction in the 25-year risk of developing T2D for a
random person over the age of 25 was 0.89% (0.83% to
0.95%). At a population level, this equates to 388,369
(362,939 to 413,800) fewer people developing T2D over
25 years.
From this reduction in the risk of developing T2D
there is a consequent reduction in the risk of developing
the complications of T2D. This in turn could reduce the
NHS burden of treating those complications for each in-
dividual as well as increases an individual’s quality of life.
Specifically over 25 years the modelling predicts that
consumption of an additional daily serving of yoghurt in
the whole adult population over 25 years old in the UK
would reduce the number of people with:
 A first cerebrovascular event (stroke) by 4,811
(95% CI: 1,968, 7,654);
 Ischemic heart disease by 3,499 (1,074, 5,923);
 Heart failure by 1,749 (35, 3,464);
Table 3 Model disease incidence and prevalence rates
Condition Prevalence source Incidence source
Diabetes (Type 2) Scottish Diabetes Survey 2013 [31] Scottish Diabetes Survey 2013 [31]
Ischemic heart disease British Heart Foundation 2012 [32] British Heart Foundation 2012 [32]
Heart failure Welsh Health Survey 2010 [33] British Heart Foundation 2012 [32]
Myocardial infarction British Heart Foundation 2012 [32] British Heart Foundation 2012 [32]
Renal replacement therapy (RRT) The Renal Registry 2012 [34] EUGLOREH [35]
Cerebrovascular disease (stroke) British Heart Foundation 2012 [32] Oxford Vascular study [36]
Diabetic retinopathy Zhang et al. (2010) [37] DARTS diabetes register McAlpine et al. (2005) [38]
Blindness Prasad et al. (2001) [39] Trautner et al. (2003) [40]
Neuropathy Abbott et al. (2001) [41] Abbott et al. (2002) [41]
Lower limb amputation Ahmad et al. (2014) [42] Johannesson et al. (2009) [43]
Table 4 Increase in risk of conditions with T2D
Disease Increase in risk
Ischemic heart disease 76%
Heart failure 73%
Myocardial infarction 55%
RRT 64%
Cerebrovascular disease (stroke) 34%
Lower limb amputation 287%
Table 5 Source of mortality rates
Disease Source
Ischemic heart disease NICE CG108. (2006) [44]
Heart failure, year one Cowie et al. (2000) [45]
Heart failure, after year one Hobbs et al. (2007) [46]
Myocardial infarction British Heart Foundation 2012 [32]
RRT The Renal Registry 2012 [34]
Cerebrovascular disease (stroke) British Heart Foundation 2012 [32]
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 A first myocardial infarction by 1,749 (35, 3,464);
 Requiring RRT by 437 (−420, 1,295);
 Diabetic neuropathy by 13,558 (8,786 to 18,330);
 Lower limb amputation by 3,936 (1,365 to 6,508).
The biggest driver of both cost savings and QALY
gains in the model results from the reduction in people
with T2D itself rather than a reduction in complications.
Savings from direct treatment costs of T2D accounts for
91.5% of the total model savings and approximately 85%
of the QALY gains.
The model also suggested that increased yoghurt con-
sumption to an average of 125g per day would reduce
overall mortality over 25 years by 0.005% (0.001% to
0.009%). This equates to there being 2,187 (95% CI: 270
to 4,104) more people who would still be alive after 25
years if yoghurt consumption increased to an average of
125g.
We undertook sensitivity analyses of the lower and
upper confidence interval for the risk reduction of an
extra daily serving of yoghurt on T2D risk reported in
Chen adjusted for 125g consumption (0.85 to 0.98). This
results in a potential saving to the NHS of an increase in
average consumption to 125g a day at a population level
of between £0.48 billion and £3.80 billion. QALY savings
generated varied between 60,940 and 429,831 and deaths
averted between 1,749 and 4,374.
Discussion
We have demonstrated that if the correlation relation-
ship reported in Chen of increasing yoghurt consump-
tion is causative, then increasing yoghurt consumption
could be an effective policy for reducing the incidence of
T2D. The patient-level simulation model predicts that if
in the UK the average consumption of yoghurt increased
from 20.4g to 125g daily (an additional 100g) in people
over the age of 25 years old, nearly 400,000 fewer people
would develop T2D over the next 25 years. Such an
approach fits well with National Institute for Health and
Clinical Excellence (NICE) 2015 Clinical Guidelines to
integrate dietary advice into prevention and treatment
of T2D, as well as United Nation goals to reduce the
impact of non-communicable diseases (NCDs), such
as T2D, by reducing modifiable risk factors for NCDs
associated with unhealthy diet, physical inactivity and
obesity [25].
In terms of the NHS, an increase in the average con-
sumption of conventional yoghurt could help attenuate
Table 6 Estimated base case individual and total UK costs and savings over 25 years for an average daily yoghurt intake of 125g.
(Means and 95% CI)
Individual (average) costs UK population costs
Costs Current scenario Yoghurt scenario Savings Current scenario Yoghurt scenario Savings
5 Years £5,984
(£5,966, £6,002)
£5,981
(£5,963, £5,998)
£3.21
(£2.65, £3.77)
£261,710m
(£260,941m, £262,480m)
£261,570m
(£260,801m, £262,339m)
£140m
(£116m, £165m)
10 Years £10,883
(£10,854, £10,911)
£10,871
(£10,842, £10,900)
£11.6
(£10.09, £13.1)
£475,955m
(£474,697m, £477,214m)
£475,448m
(£474,192m, £476,705m)
£507m
(£441m, £573m)
15 Years £15,028
(£14,990, £15,067)
£15,005
(£14,966, £15,043)
£23.65
(£21.08, £26.23)
£657,270m
(£655,579m, £658,961m)
£656,235m
(£654,549m, £657,922m)
£1,034m
(£922m, £1,147m)
20 Years £18,547
(£18,499, £18,595)
£18,509
(£18,461, £18,557)
£37.91
(£34.31, £41.51)
£811,149m
(£809,049m, £813,249m)
£809,491m
(£807,397m, £811,584m)
£1,658m
(£1,500m, £1,816m)
25 Years £21,493
(£21,436, £21,550)
£21,438
(£21,382, £21,495)
£54.35
(£49.87, £58.82)
£939,994m
(£937,509m, £942,480m)
£937,617m
(£935,140m, £940,095m)
£2,377m
(£2,181m, £2,573m)
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NHS expenditure on diabetes already predicted to in-
crease to 17% of the total resources by 2035 [13]. Apply-
ing the average saving to the UK population over the age
of 25 would generate total discounted savings to the
NHS of approximately £140 million over five years that
would increase to £2.4 billion over 25 years if average
consumption increased to 125g.
Additional benefits from increased yoghurt consump-
tion might accrue from direct effects on cardiovascular
risks. Evidence that fatty acids in dairy may help improve
glucose homeostasis [9], and daily consumption of pro-
biotic yoghurt has the potential to improve cardiovascu-
lar disease risk factors associated with diabetes [26],
provides a rationale for incorporating the consumption
of yoghurt into this dietary advice.
Yoghurt consumption can also be recommended in
addition to other, more targeted interventions, as the
financial cost of purchasing the yoghurt falls upon the
individual rather than the NHS; if the yoghurt was a re-
placement for other snacks rather than an additional
snack, the cost to the individual might be negligible. In a
recently published meta-analysis, Gijsbers supports the
findings of the Chen study indicating that yoghurt intake
may be non-linearly associated with lower risk of T2D,
reporting a 14% lower risk for an intake of 80 to 125g
per day compared with zero consumption, which ap-
pears to be in line with the absolute risk reduction of
our base case [27].
Given the rapidly increasing prevalence of T2D, the
findings of this research offer implications for cost-
saving measures which could help alleviate the economic
burden of T2D, and relieve pressure on the health care
infrastructures in the long term in populations beyond
the UK.
Limitations in model
All the analyses related to individuals over the age of 25
and so the model and economic results generated are
only for people over the age of 25 years old; however
this is reasonable for the condition as T2D is more com-
mon after the age of 45 [28].
The Chen meta-analysis [12], on which this research is
based, provided longitudinal data from a large number of
patients which provides evidence on the RR of developing
T2D with different levels of yoghurt consumption based
upon the correlation between the two. The Chen data was
pooled from retrospective food frequency questionnaires
capturing participant food intake over the course of a year,
Table 7 Estimated base case individual and total UK QALYs and savings over 25 years for an average daily yoghurt intake of 125g
Individual (average) QALYs UK population QALYs
QALYs Current scenario Yoghurt scenario Gained QALYs Current scenario Yoghurt scenario Gained QALYs
5 Years 4.3743
(4.3684, 4.3803)
4.3747
(4.3687, 4.3807)
4.3743
(4.3684, 4.3803)
191m
(191m, 192m)
191m
(191m, 192m)
0.017m
(0.015m, 0.020m)
10 Years 8.0515
(8.0372, 8.0657)
8.0528
(8.0386, 8.067)
8.0515
(8.0372, 8.0657)
352m
(352m, 353m)
352m
(352m, 353m)
0.060m
(0.052m, 0.067m)
15 Years 11.1406
(11.1175, 11.1637)
11.1434
(11.1203, 11.1665)
11.1406
(11.1175, 11.1637)
487m
(486m, 488m)
487m
(486m, 488m)
0.124m
(0.109m, 0.139m)
20 Years 13.6927
(13.6608, 13.7245)
13.6973
(13.6654, 13.7291)
13.6927
(13.6608, 13.7245)
599m
(597m, 600m)
599m
(598m, 600m)
0.200m
(0.177m, 0.223m)
25 Years 15.7573
(15.7172, 15.7975)
15.7637
(15.7235, 15.8038)
15.7573
(15.7172, 15.7975)
689m
(687m, 691m)
689m
(688m, 691m)
0.276m
(0.246m, 0.307m)
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so there is likely to be some recall bias in reporting
amounts of foods consumed. Chen compiled data from
prospective cohort studies, which allows establishment of
statistical associations between events. This does not
provide direct proof of effect, individual studies have as
much as possible adjusted for confounding factors but the
possibility of residual confounding cannot be discarded.
To demonstrate causality, randomised controlled inter-
vention trials of increasing yoghurt consumption would
be needed. It may be that such studies, including in indi-
viduals under 25 years old [29], should now be planned
and undertaken. The Chen meta-analysis did not differen-
tiate between plain, flavoured and sweetened yoghurt.
Results from 3 recent prospective cohorts indicate that
weight loss is observed even with sweetened yoghurt con-
sumption, although the benefit is higher for those who eat
yoghurt with a low glycaemic load [10]. In addition, it has
been reported that, when observing consumer sweetening
behaviour in contextualised conditions, on average a
greater amount of sugar is added in plain yoghurt than
that found in commercial pre-sweetened yoghurts [30].
Further research could investigate differences in diabetes
incidence rates across the various types of yoghurt.
Conclusions
Increasing yoghurt consumption in the adult population
of the UK by 100g per day could generate substantial
cost savings to the NHS as well as significant patient
benefit through reductions in the incidence of T2D if
the causal relationship between yoghurt consumption
and reduced levels of diabetes seen in published studies
is confirmed.
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